Hemoglobin Volga Hastalığı, Teşhisi ve Tedavisi
Özet
Hemoglobin (Hb) Volga hastalığı, 11. kromozom üzerindeki 27. kodonda meydana gelen GCC>GAC nokta mutasyonu sonucu alanin aminoasidinin aspartik aside dönüşmesiyle ortaya çıkan, heterozigot özellikli, nadir bir kararsız hemoglobinopati ve kronik hemolitik anemi türüdür. Bu mutasyon, hemoproteini dengesizleştirerek artan oto-oksidasyon oranı ve serbest radikaller sebebiyle eritrosit zarlarına zarar verir, bu da hemolitik sendroma ve ani hemolitik krizlere yol açar. Fiziksel bulguları arasında splenomegali (büyük dalak), hızlı değişen vücut ısısı, sürekli yorgunluk ve soluk ten yer alırken; laboratuvarda Heinz cisimcikleri, bazofilik stippling, retikülositoz, anizositoz, düşük hemoglobin konsantrasyonu (MCHC) ve düşük eritrosit değerleri gözlenir. Hb Volga elektroforezde normal bir model gösterebildiğinden ve retikülositoz ile karıştırılabildiğinden standart hematolojik analizler ve HPLC tanı için yetersiz kalabilmekte, kesin teşhis için RT-PCR ve DNA sekanslaması gibi moleküler analizler gerekmektedir. Tam bir tedavisi bulunmayan hastalıkta, eritrosit ömrünü uzatmak ve hematolojik değerleri iyileştirmek için splenektomi uygulanmakta, ayrıca HbF seviyesini artırarak krizleri önlemek amacıyla hidroksiüre (HU) tedavisi dikkatle tercih edilmektedir.
Hemoglobin Volga disease is a rare, heterozygous, unstable hemoglobinopathy and chronic hemolytic anemia caused by a GCC>GAC point mutation at codon 27 on chromosome 11, resulting in the substitution of alanine with aspartic acid. This mutation destabilizes the hemoprotein due to an increased auto-oxidation rate and free radicals, damaging erythrocyte membranes and causing hemolytic syndromes as well as sudden hemolytic crises. Its physical symptoms include splenomegaly, rapidly changing body temperature, chronic fatigue, and pale skin, while laboratory findings present Heinz bodies, basophilic stippling, reticulocytosis, anisocytosis, low mean corpuscular hemoglobin concentration (MCHC), and low red blood cell counts. Since Hb Volga can mimic a normal pattern on hemoglobin electrophoresis and can be confused with reticulocytosis, standard hematological analyses and HPLC may fall short for a definitive diagnosis, making molecular analyses such as RT-PCR and DNA sequencing mandatory for exact identification. Although there is no complete cure for the disease, splenectomy is performed to prolong erythrocyte lifespan and improve hematological variables, and hydroxyurea (HU) therapy is carefully utilized to increase HbF levels and prevent crises.
Referanslar
Nadir Hastalıklar Ağı. (10.02.2022 tarihinde https://www.nadirhastaliklaragi.org.tr/ adresinden ulaşılmıştır).
Yates AM, Mortier NA, Hyde KS, et al. The diagnostic dilemma of congenital unstable hemoglobinopathies. Pediatr Blood Cancer; 2010; 55(7):1393-1395. doi: 10.1002/pbc.22702.
Hemoglobin Varyantları ve Talasemi Veritabanı. (10.02.2022 tarihinde https://globin.bx.psu.edu/cgi-bin/hbvar/query_vars3?mode=output&display_format=page&i=280 adresinden ulaşılmıştır).
Luo HY, Heeney M, Wang WC, et al. Hemoglobinopathies mimicking Hb S/beta-thalassemia: Hb S/S with alpha-thalassemia and Hb S/Volga. Am J Hematol; 2006; 81(5):361-365. doi: 10.1002/ajh.20562.
Loovers HM, Tamminga N, Mulder AB, et al. Clinical Course of Two Children with Unstable Hemoglobins: The Effect of Hydroxyurea Therapy. Hemoglobin; 2016; 40(5):341-344. doi: 10.1080/03630269.2016.1232655.
Carrell RW, Winterbourn CC, Rachmilewitz EA. Activated oxygen and haemolysis. Br J Haematol; 1975; 30(3):259-264. doi: 10.1111/j.1365-2141.1975.tb00540.x.
Plaseska D, Koceva S, Rasovic N, et al. Hb Volga [beta 27(B9)Ala-->Asp]: detection of a de novo mutation by Ava II digestion of PCR-amplified DNA. Hemoglobin; 1993; 17(3):209-215. doi: 10.3109/03630269308998895.
Perutz MF, Rossmann MG, Cullıs AF, et al. Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. resolution, obtained by X-ray analysis. Nature; 1960; 185(4711):416-422. doi: 10.1038/185416a0.
Sabath DE. Molecular Diagnosis of Thalassemias and Hemoglobinopathies: An ACLPS Critical Review. Am J Clin Pathol; 2017; 148(1):6-15. doi: 10.1093/ajcp/aqx047.
Benz EJ, Ebert BL, Hoffman R, et al. Hemoglobin variants associated with hemolytic anemia, altered oxygen affinity, and methemoglobinemias. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018: chap 43. p. 645-652.
Bunn HF, Nagel RL, Orkin SH, et al. Hematology of Infancy and Childhood. Vol. 7. Philadelphia: Saunders; 2009. Hemoglobins: Normal and Abnormal; p. 911-948.
Sözen M, Karaaslan C, Oner R, et al. Severe hemolytic anemia associated with Hb Volga [beta27(B9)Ala-->Asp]: GCC-->GAC at codon 27 in a Turkish family. Am J Hematol; 2004;76(4):378-82. doi: 10.1002/ajh.20128.
Marengo-Rowe AJ. Structure-function relations of human hemoglobins. Proc (Bayl Univ Med Cent); 2006; 19(3):239-45. doi: 10.1080/08998280.2006.11928171.
Winterbourn CC, Carrell RW. Studies of hemoglobin denaturation and Heinz body formation in the unstable hemoglobins. J Clin Invest; 1974; 54(3):678-89. doi: 10.1172/JCI107806.
Idelson LI, Didkowsky NA, Filippova AV, et al. Haemoglobin Volga P27, (B9) ala-wasp, a new highly unstable haemoglobin with a suppressed charge. FEBS Lett; 1975, 58:122-125. doi.org/10.3109/03630267809005360
Kuis-Reerink JD, Jonxis JH, Niazi GA, et al. Hb-Volga or alpha 2 beta 2 27(B9) Ala replaced by Asp. An unstable hemoglobin variant in three generations of a Dutch family. Biochim Biophys Acta; 1976; 439(1):63-69. doi: 10.1016/0005-2795(76)90161-6.
Brennan SO, Ekert H, Tauro G, et al. New Zealand Med. J., 1976; 83:162.
Falcioni G, Grelloni F, Bertoli E, et al. Influence of splenectomy on the properties of erythrocytes with hemoglobin Volga disease. Clin Chim Acta; 1991; 196(2-3):153-158. doi: 10.1016/0009-8981(91)90068-n.
Hardison RC, Chui DH, Giardine B, et al. HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat; 2002; 19(3):225–233. doi: 10.1002/humu.10044.
Wang WC, Carter H, Choitz HC, et al. Characterization of Hb Volga [beta 27(B9)Ala-->Asp] and Hb J-Wenchang-Wuming [alpha 11(A9)Lys-->Gln] in the population of the United States. Hemoglobin; 1993;17(1):67-71. doi: 10.3109/03630269308998886.
Ockelford PA, Liang AY, Wells RM, et al. Hemoglobin Volga, β27 (B9) Ala→Asp: Functional and Clinical Correlations of an Unstable Hemoglobin, Hemoglobin; 1980; 4(3-4): 295-306. doi: 10.3109/03630268008996212.
Steinberg MH, Adams JG 3rd. Hemoglobin A2: origin, evolution, and aftermath. Blood; 1991; 78(9):2165-2177.
Blanke S, Johnsen A, Wimberley PD. Hb Volga [B27 (B9) AlA----AsP], a possible de novo mutation in a Danish person. Hemoglobin; 1989;13(5):489-491. doi: 10.3109/03630268908998087.
Ozsoylu S, Gurgey A. A case of hemolytic anemia due to erythrocyte pyrimidine 5'-nucleotidase deficiency. Acta Haematol; 1981; 66(1):56-58. doi: 10.1159/000207094.
Balta G, Gumruk F, Akarsu N, et al. Molecular characterization of Turkish patients with pyrimidine 5' nucleotidase-I deficiency. Blood; 2003; 102(5):1900-1903. doi: 10.1182/blood-2003-02-0628.
Spencer S. Ecless Health Sciences Lıbrary Universıty Of Utah- Health Education Assets Library- (11.02.2022 tarihinde https://collections.lib.utah.edu/ark:/87278/s6dn775k adresinden ulaşılmıştır).
The Largest Library of Medical Education in the World. (11.02.2022 tarihinde www.statpearls.com adresinden ulaşılmıştır).
Falcioni G, Grelloni F, De Sanctis G, et al. Enzymatic antioxidative defence of erythrocytes in an Italian family with Hb Volga or alpha 2 beta 2 27 (B9) Ala----Asp. Clin Chim Acta; 1988; 178(3):345-347. doi: 10.1016/0009-8981(88)90243-4.
Bozzi A, Mavelli I, Finazzi A, et al. Enzyme defense against reactive oxygen derivatives. II. Erythrocytes and tumor cells. Mol Cell Biochem; 1976; 10(1):11-16. doi: 10.1007/BF01731676.
Helvaci M. Sickle Cell Diseases. Mustafa Kemal Üniversitesi Tıp Dergisi. 2015; 6(22): 25-34. doi: 10.17944/mkutfd.34012.
